Abstract
Increased intraocular pressure (IOP) is often associated with glaucoma, a leading cause of irreversible vision loss. Commonly, multiple medications are required to achieve IOP control in glaucoma or ocular hypertension. The fixed combination of timolol and dorzolamide is among the most commonly used antiglaucoma medications. It is more effective than either of its components used as monotherapy, and has an IOP lowering ability that is slightly less than the concomitant use of the components. The fixed combination allows the simplification of a multidrug regimen by reducing the total number of drops and preservative instilled per day, avoids washout effect from rapid sequence instillation of individual drops, and may improve adherence to chronic therapy. Although fixed combination medications are increasingly popular with several combinations available worldwide, the fixed dorzolamide–timolol combination remains the only fixed combination approved in the USA.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
